NCT00000946View on ClinicalTrials.gov

A Study to Test the Safety of Three Experimental HIV Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2001

Conditions
HIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL

HIV p24/MF59 Vaccine

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (7)

14642

Univ. of Rochester AVEG, Rochester

21205

JHU AVEG, Baltimore

35294

UAB AVEG, Birmingham

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

63110

St. Louis Univ. School of Medicine AVEG, St Louis

98104

FHCRC/UW Vaccine CRS, Seattle

98109

UW - Seattle AVEG, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH